We believe our PyraDerm™ solution is the next generation of drug delivery, with the ability to painlessly delivery large, as well as small, molecule therapies transdermally. PyraDerm™ utilizes our novel “Programmable release with optimal tuning”™ mechanism, which enables delivery into a specific layer of the skin over a desired period of time. We are interested in working with you to evaluate your application and to support product commercialization. We believe that by working together we can

provide proof of principle in early stage clinical trials for the target drugs and offer to our potential partners a solution not easily replaced by competitive technologies

develop a custom platform solution that could be applied to a wide range of therapeutics

extend the patent life of existing drugs by developing a customized transdermal formulations

bring new life to therapeutics that may have been not suitable for existing delivery approaches such as oral

If you are interested in building your business with Apogee please contact:

Herbert M. Stein
Chief Executive Officer
Apogee Technology, Inc.
Tel. 781.769.9100
Email: hstein@apogeebio.com